Company / Cash & Equivalents
CAPRICOR THERAPEUTICS, INC. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$287.8M
FY2025
5-year range
$9.6M / $287.8M
FY2021-FY2025
Trend
+2450.3%
vs FY2024
Sector context
#65 of 206
Health Care
What the data says
Cash & Equivalents changed +2450% YoY in FY2025, a notable deviation from the 9-year average annual change of +356%.
Based on SEC 10-K filings.
$288M in FY2025 with a 5-year CAGR of +54.5%.
Improved from $15M to $288M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +210.6%
- 5-Year CAGR
- +54.5%
- 10-Year CAGR
- -
Sector benchmark
#65 of 206 in Health CareTop 32% of 206This company $287.8M Sector average $672.3M
▼
-57.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +54.5%, indicating consistent growth.
- In FY2025, cash & equivalents increased 2450.3% year-over-year.
- Ranks #65 out of 206 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $287.8M | +2450.3% |
| FY2024 | $11.3M | -23.2% |
| FY2023 | $14.7M | +53.0% |
| FY2022 | $9.6M | -72.5% |
| FY2021 | $34.9M | +6.8% |
| FY2020 | $32.7M | +737.7% |
| FY2019 | $3.9M | -8.5% |
| FY2018 | $4.3M | -30.6% |
| FY2017 | $6.1M | +91.6% |
| FY2016 | $3.2M | -42.5% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026